Health · Ai
K36 Therapeutics, Inc.
K36 Therapeutics is a Cambridge, Massachusetts clinical-stage biotech developing first-in-class oral small-molecule inhibitors of NSD2/MMSET, an epigenetic enzyme that drives hard-to-treat cancers. Its lead candidate, gintemetostat (KTX-1001), is in Phase 1 for relapsed/refractory multiple myeloma carrying the t(4;14) translocation, and a second program, KTX-2001, targets metastatic castration-resistant prostate cancer. Backed by Atlas Venture, F-Prime Capital, Eight Roads Ventures, Nextech Invest and Bristol Myers Squibb, K36 has raised roughly $100M+ to translate chromatin biology into precision cancer medicines.